A new advisory statement for medications containing benzocaine will warn consumers not to give them to children under two years of age, with the change expected to be implemented from 01 Sep 2020.
The move follows a consultation process last year during which the only respondent was the Australian Self Medication Industry.
ASMI commented on the proposed warning statement for medicines for topical oral use that contain benzocaine, noting that there are no benzocaine-containing infant teething products on the Australia Register of Therapeutic Goods, "so the risk of these products being selected by consumers for use in this age group is very low".
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jan 19
